[Problems and future direction of preoperative systemic therapy for patients with operable breast cancer].
Zhang
Bin
B
zhangbin@medmail.com.cn
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D000077143:Docetaxel; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D011300:Preoperative Care; D012074:Remission Induction; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage*; D014230:Triazoles / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D009570:Nitriles; D043823:Taxoids; D014230:Triazoles; D000077143:Docetaxel; D014750:Vincristine; D000077289:Letrozole; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone